



## ***IN VITRO* SCREENING OF THE PROBIOTIC POTENTIAL OF *LACTOBACILLUS* AND *ENTEROCOCCUS* STRAINS ISOLATED FROM HUMAN BREAST MILK, FECES OF BREAST-FED INFANTS AND ANIMAL MILK (GOAT, COW AND BUFFALO)**

Shaik Parvinnisa<sup>1</sup>, Farhath Khanum\*<sup>1</sup> Chandrasekhar. N<sup>2</sup>, Girish Kumar.B<sup>2</sup> and Renuka.B<sup>1</sup>

<sup>1</sup>Defence Food Research Laboratory- Defence Research and Development Organization (DFRL-DRDO), Mysore-570011

<sup>2</sup>Research and Development Center, Department of Chemistry, Shridevi Institute of Engineering and Technology, Sira Road, Tumakuru - 572106, Karnataka, India.

\*Corresponding Author Email: [farhathkhanum@gmail.com](mailto:farhathkhanum@gmail.com)

### **ABSTRACT**

This study sought to investigate the probiotic potent of lactic acid bacteria isolated from animal raw milk, human breast milk and infant fecal matter. A total of 200 LAB strains have been isolated, among this four *Lactobacillus* spp and four *Enterococcus* spp. have been screened for their functional properties, among these *Lactobacillus para casei* NB16 isolated from human breast milk was capable to survive at 1% bile salt, pH 2.0 and SGJ for 4 h without losing viability and ability to grow in a range of temperatures at 15- 50°C, pH 3-9 and salt concentration up to 8 %. All LAB strains exhibited inhibitory activity towards wide range of food borne pathogens, in addition, NB12, and NB16 have been found to be resistant to 16 antibiotics out of 17 except Chloramphenicol and fermented 17 sugars out 20. Adhesion percentage of 8 isolates to Hydrocarbons up to (96%), auto-aggregation up to (90%) and co-aggregation with *Escherichia coli* MTCC 40 up to (62%) was observed and 16S rDNA sequence confirmed NB12, NB 14, NB 113 as *Lactobacillus para casei*, NB16 as *Lactobacillus casei*, NB10, NB44, NB94 as *Enterococcus faecium* and NB7 as *Enterococcus faecalis* respectively. Probiotic functional properties of isolates have been characterized and isolates were identified by using molecular methods.

### **KEY WORDS**

*Enterococcus faecalis*, Feces of breastfed infants, Human breast milk, *Lactobacillus casei*.

### **I. INTRODUCTION**

Human beings and animals use probiotics as a part of the healthy diet to have safe, natural and effective health-promoting benefits [1, 2, 3]. According to the definition by the World Health Organization (WHO), "live microorganisms which when administered in adequate amounts confer a health benefit on the host" [4, 5, 6]. The genera of *Lactobacillus*, *Lactococcus*, *Bifidobacteria*, *Streptococcus*, *Enterococcus*, *Saccharomyces* and numerous strains of yeast have

been considered as probiotics [1, 7, 8]. However, lactic acid bacteria are considered as the main group of probiotics. Several species of these genera are "Generally Recognized as Safe (GRAS)" by the FDA (US food and drug administration) and they are technologically appropriate for industrial approaches [1, 9].

To date, several lactic acid bacterial species have been isolated from the dairy products. The investigations have revealed that the infectious disorders decreased

among breastfed infants and rural population who consumed unpasteurized milk in contrast to pasteurized milk products and also indicated that certain unique elements are existing in raw milk to provide protection towards infectious diseases by producing organic acids and hydrogen peroxide [10, 11, 12, 13]. Due to these observations, raw milk and infant feces are recognized as one of the attractive sources and natural habitats of lactic acid bacteria, which play an essential role in the prevention of infectious disorder in the host [14]. Numerous studies have assessed the probiotic potential of the isolated lactic acid bacteria such as their tolerance to bile salt, acidic pH, aggregation, immunity modulation characteristics, survival ability when co-administered with antibiotics, inhibitory activity towards pathogens, adherence potential to intestinal epithelial cells to form barriers in preventing colonization by pathogens [15, 16, 17, 18, 19, 20, 21]. Probiotics were recommended for several health benefits in human beings and animals such as promoting proper digestion, enhancing immunity and amplifying resistance to infection [22]. Removal of carcinogens, reducing cholesterol level, synthesis and improving the bioavailability of nutrients, relief from lactose intolerance [22, 23] control of diarrhea [24] and inflammatory bowel illnesses [25] and anti-mutagenic effect [26, 27]. The objective of the current study was isolation, identification and characterization of potent probiotic lactic acid bacteria from human breast milk and milk from goat, cow, buffalo and infant fecal matter.


## II. MATERIALS AND METHODS

### Isolation of Lactic acid bacteria

Samples were collected aseptically from the habitats about lactic acid bacteria (Table 1), stored at  $4\pm 1^\circ\text{C}$  and enumerated within an hour of sampling through serial dilution method with sterile saline (NaCl-0.85%) pH 7.0. Aliquot (100  $\mu\text{l}$ ) of the samples were placed on MRS agar (pH 6.8 and pH7.0) by spread plate method then plates were incubated at  $37^\circ\text{C}$  for 24–48 h in anaerobic condition [28]. Based on the colony color (white and creamy) and morphology, colonies were randomly selected and transferred to MRS agar plates by using streaking methods, pure colonies were preserved on MRS broth with 40 % sterile glycerol at  $-20^\circ\text{C}$ . A total of 200 pure cultures were isolated and evaluated for probiotics morphological and biochemical characterization as described by Bergey's manual of systematic bacteriology [29, 30, 31]. Eight strains were carefully selected as probiotics from the screened 200 isolates based on morphological and biochemical characteristics (morphological characteristics - Gram-positive, catalase-negative, non-motile, non-spore-forming, irregular short rods and cocci) and biochemical characteristics (growth at  $15-50^\circ\text{C}$ , tolerance of pH 2-9, tolerance of NaCl concentrations upto 8%, sugars fermentation (17 sugars fermented out of 20 tested sugars). These 8 isolates were further tested for probiotic functional properties and genotypic characterization (Figure 1).

**Table 1. Sources of lactic acid bacteria.**

| Isolation Sources               | No. of samples | No. of isolates | Location  |
|---------------------------------|----------------|-----------------|---|
| Colostrum                       | 2              | 15              | Shridevi Institute of Medical Sciences& Research Hospital, Tumkur, Karnataka, India |
| Fore milk                       | 4              | 22              | Shridevi Institute of Medical Sciences& Research Hospital, Tumkur, Karnataka, India |
| Goat milk                       | 2              | 16              | Private farms, Mysore, Karnataka, India   |
| Cow milk                        | 2              | 16              | Mysore, Karnataka, India  |
| Kefir grains                    | 1              | 26              | Mysore, Karnataka, India  |
| Buffalo milk                    | 2              | 12              | Mysore, Karnataka, India  |
| Breast feed Infant fecal matter | 8              | 87              | Shridevi Institute of Medical Sciences& Research Hospital, Tumkur, Karnataka, India |
| <b>Total</b>                    | <b>21</b>      | <b>200</b>      |   |

**Figure 1.: Lactic acid bacteria**


a: Lactic acid bacteria from Breast milk, b: Cocci, c: Bacilli Gram-positive LAB observed under phase contrast microscope d & e: Field Emission Scanning Electron Microscopy (FESEM) image (2000X and 7000X) of *Lactobacillus*.

### Probiotic Properties:

#### Acid, Bile and Synthetic Gastric Juice tolerance test

Selected isolates were tested for tolerance to acidic pH, bile and synthetic gastric juice as described by previous studies [10, 26, 32, 33]. Active culture (18 h) with 0.28 optical density value at 600 nm was inoculated (10% v/v) on to MRS broth adjusted to acidic pH- 2.0 with 0.1 N HCl, MRS medium was enriched with 1% ox bile, in Synthetic Gastric Juice { ( 8.3 g of protease peptone , 3.5g of glucose, 2.05g of NaCl, 0.6 of

KH<sub>2</sub>PO<sub>4</sub>, 0.37g of KCl , 0.11 g of CaCl<sub>2</sub>, 0.05 g of bile ,13.3 mg of pepsin and 0.1g of lysozyme ; as per liter adjusted to pH- 2.5). The medium was filter sterilized using 0.22 µm membrane filters and incubated at 37°C for 4 hours. Survivability of the cells from 0 h to 4 h was determined by serial dilutions of samples in (0.85% NaCl) physiological saline then placed on MRS agar, incubated for up to 48 h at 37°C. The rate of survivability was calculated by using the formula [34].

$$\% \text{ Survival} = \log \text{ number of survived cells (CFU/ml)} / \log \text{ number of inoculated cells (CFU/ml)} \times 100 \text{ ----- (1)}$$

The cell survival was determined, and the results are tabulated.

#### Bacterial Adhesion to Hydrocarbons Assay

The bacterial adhesion to hydrocarbons (BATH) test was carried out to assess the adherence ability of LAB isolates using hydrocarbon- xylene, toluene, chloroform, and ethyl acetate as described by previous reports. [10,35,36,37,38]. 1ml of 18 h cultures were harvested by centrifugation at 6500 rpm for 5min at 4°C, washed twice with phosphate buffered saline (PBS; 140mm NaCl, 3Mm KCl, 8Mm Na<sub>2</sub>HPO<sub>4</sub>, 2Mm KH<sub>2</sub>PO<sub>4</sub>,

pH7.2) then re-suspend in the same PBS buffer. The cell suspension was adjusted to obtain an absorbance of 1.0 at 600 nm, 200µl of hydrocarbon was added to 200µl of bacterial suspension then mixed thoroughly by using vortex for 2 min then allowed to stand for 1 h at 37° C for phase separation. The bottom aqueous phase was removed carefully then its absorbance was measured at 600 nm. The decrease in optical density (OD) correlates with the measurement of the cell surface hydrophobicity (H %) calculated by the formula,

$$\text{Cell surface hydrophobicity H\%} = [(A_0 - A)/A_0] \times 100 \text{ ----- (2)}$$

Where, A<sub>0</sub> and A are the absorbances before and after extraction together with hydrocarbons.

#### Autoaggregation

Auto-aggregation assay was carried out according to the previous studies [39, 26, 32, 40]. Isolates were grown at 37°C for 24 to 48 hrs on MRS broth. The cells were harvested through centrifugation for 10 min at 7000 rpm, washed twice and re suspended in the PBS, pH 7. A cell suspension (4 ml) was vortexed for 10 sec then

auto-aggregation was determined after 3 hrs and 5 hrs of incubation at 37°C. An aliquot (0.1 ml) of the upper layer (suspension) of PBS after incubation was transferred to another tube with 3.9 ml of PBS absorbance (A) was determined at 600 nm. The percentage of auto-aggregation was calculated by the usage of the equation [41]:

$$1 - (A_t/A_0) \times 100 \text{ ----- (3)}$$

Where, A<sub>t</sub> and A<sub>0</sub> signify the absorbance of at time 5 h and 0 h, respectively.

### Co-aggregation assay

Co-aggregation assays have been executed in accordance with the previous reports [39, 42, 26, 40]. The cells were harvested by centrifugation for 15 min at 5000 rpm, washed twice and re-suspended in phosphate buffered saline to assign viable counts of approximately

$10^8$  CFU/ml. Equal volumes (2ml) of each cell suspension was combined together in pairs through vortexing for 10 s. The absorbance of the cell suspensions at 600 nm was measured after 5 h of incubation at 37°C. The percentage about co aggregation was calculated using the equation [41]:

$$\text{Coaggregation (\%)} = \frac{[(Ax+Ay)/2]-A(x+y)}{(Ax+Ay) / 2} \times 100$$

Where, x and y signify each of the pair strains within the control tubes, then (x + y) the mixture.

### Antibacterial assay

The inhibitory effect of selected LAB isolates was determined using the well-diffusion approach [43, 26, 19, 44]. To determine the inhibitory capability of the selected strains towards pathogens, an overnight culture of the pathogenic strain (*Escherichia coli* MTCC 40& ATCC 10536, *Bacillus aureus* MTCC1306, *Salmonella Para typhi* ATCC9150, *Salmonella Typhi murium* MTCC91, *Salmonella Arizonae* ATCC 13314 and *Shigella Boydii* ATCC 9207) was inoculated to BHI (Brain Heart Infusion) media and incubated at 37°C (approximately 100µl for 1ml BHI broth). Wells about 5mm diameter were cut into MRS agar plates and 50 µL of LAB culture supernatant neutralized with 0.1 N NaOH was added to all MRS agar wells. The indicator pathogens (1ml) in nutrient broth were mixed in 7ml of 0.7% soft agar over layered immediately on MRS agar plates and the culture filtrate was inoculated. The inhibitory zone of lactic acid bacteria was observed after 24-48h of incubation about 37°C.

### Antibiotics susceptibility test

Antibiotics resistance of each selected isolates were assessed through the paper disc method (HiMedia Pvt. Ltd., Mumbai, India). The antibiotic discs were placed on MRS agar plates previously seeded with 18h culture, incubated at 37°C for 24-48 hr, then the diameter of the zone of the inhibition was observed, measured and expressed in mm. The susceptibility of strains used was expressed as described by previous reports [45, 46, 47, 26, 48, 49].

### Genotypic characterization

#### Qualitative and Quantitative determination of DNA

#### Isolation of chromosomal DNA using the Conventional method

In the genetic characterization, isolation, extraction then purification of genomic DNA of isolates was carried out as per the previously used methods [26, 50]. Where 5-ml of bacterial cultures were centrifuged at 1,5000rpm for 5 min to collect the cells, the cells were

re-suspended in one ml of Tris-EDTA buffer (pH 8.0) and further subjected to phenol-chloroform extraction and ethanol precipitation and the thus precipitated DNA was analyzed on 1% agarose gel. DNA concentration was determined by recording the absorbance at 260 nm (A260) in a Nanodrop spectrophotometer (Bio-Tek Instruments, Inc.).

### Polymerase chain reaction (PCR)

DNA integrity was evaluated using PCR technique [2, 22, 51, 52]. The nucleotide sequence of DNA of the isolates was carried out with 16SrDNA primer being used for the PCR amplification.

#### PCR primers\* [53].

P3 (forward primer) 5' -AGAGTTTGATCATGGCTCAG- 3'  
P13 (reverse primer) 5'-GGTACCTTGTTACGACTT- 3', this primer amplifies approximately 1500 bp length of 16S rDNA gene of any bacterium.

### Gel electrophoresis

A DNA ladder (1-kb) was used as a molecular size marker. The PCR was conducted through 30 cycles in Eppendorf master cycler gradient thermal cycler at 95°C for 40-sec denaturation, 52°C for 1 min annealing and 72°C with 1min extension. The DNA was denatured for 3 min in the beginning and later extended for 15 min at 72°C. PCR products were analyzed on 1% agarose gel (Figure 2). The amplified PCR products were purified and then amplicons were sequenced using Sanger's method. A BLAST (Basic Local Alignment Search Tool) search was performed using the obtained DNA sequence of 16S rDNA as the query sequence with the NCBI database in accordance with the query sequence similarity together with the NCBI database and the best match of resemblance was selected to identify the isolates.

### Statistical analysis

All assays were performed in triplicates and the data are expressed as Mean ± SEM (n=3) and standard deviations stability by the use of Microsoft Excel (Version 7.0).

### III. RESULTS AND DISCUSSIONS


#### Probiotic functional Properties

##### Acid, Bile and Synthetic Gastric Juice tolerance test

In order to consider lactic acid bacteria as probiotic it has to withstand the acidic condition in stomach in order to reach the gut and create suitable conditions for residence, for this it has to survive in the excessive acidic condition similar to that of human stomach pH 2.0 at least for 120 min which is the food transit period through the human stomach [54, 55]. In the present study, six out of eight isolates (NB 7, NB10, NB14, NB16, NB 44 and NB 113) showed greater than 75% and 2

isolates (NB12 and NB 94) showed less than 63% survivability after 4 h of exposing to acidic pH 2. In the present study, survival ability was variable, even within the same species (NB12, 14 & 113), (NB10, 44 & 94) and all isolates exhibited a significant reduction in survival rate. However, these results correlated with previous reports as stated that Bifidobacteria and *L. delbrueckii* subsp *bulgaricus* strain has poor survival rates at acidic pH [56, 57]. However, there are reports a better survival of 2 strains at same condition [58]. Due to these, we can conclude survivability is species and strain-specific [19] (Figure-2).

Figure 2: Acid, Bile and Synthetic Gastric Juice tolerance of LAB isolates



Survival of LAB isolates at pH 2.0, 1% bile concentration and SGJ at 37°C for 4 h, Values were exhibited as mean  $\pm$  SD in (n=3).

Tolerance to bile salts is considered a prerequisite for probiotics for their viability, colonization and metabolic activity within the host's gut as antimicrobial molecules. The magnitude of tolerance is determined by the concentration of bile salts, which perform an important role in the specific and nonspecific defense mechanism of the gut [59]. The mean intestinal bile concentration is considered to be 0.3 to 0.5% of the intestinal juice and the residence period of food within the digestive tract is considered to be 4 to 6 h [60]. In this study, 6 out of 8 isolates (NB 7, NB10, NB14, NB16, NB 44 and NB 113) showed greater than 78% and 2 isolates (NB12 and NB 94) showed less than 63% survivability after 4 h exposure to 1% bile. In the present study, survival capacity was variable even within the same species (NB12, 14 & 113), (NB10, 44 & 94) and overall a small reduction has been found in survivability of all isolates. These findings correlate with previous studies [57, 58]. However, there are some reports which have stated as *Weissella* and *Lactobacillus* strains found to be viable at 1% bile, *W. koreensis* FK121 and *L. crispatus* G19 have been tolerant to bile and acid concentrations. Due to

these, we can conclude survivability was species and strain-specific [51, 32] (Figure-2).

In order to work as a probiotic, the bacteria should survive in gastric juice (low pH) in the stomach and digestive enzymes and then bile acids in the duodenum [61]. Generally, 2.5 L of the gastric juice [62] and 1 L of the bile [63] are produced in the human gastrointestinal tract per day. In the current study, 6 out of 8 isolates (NB 7, NB10, NB14, NB16, NB 44 and NB 113) showed greater than 75% and 2 isolates (NB12 and NB 94) showed less than 61% survivability. The viability of probiotic strains in gastric juice depends upon their intrinsic tolerance to the adverse environment, the availability of food materials with fat and certain proteins increases the survival rate of microorganisms in gastric transit [56,64] (Figure-2).

##### Bacterial Adhesion to Hydrocarbons (BATH) assay


The probiotics adherence potential to the gastrointestinal epithelial cells is considered a prerequisite to colonize in the human digestive tract and exert health benefits and for the exclusion of enteropathogenic bacteria [65, 66]. Adhesion is a non-specific physical interaction between two surfaces;



adhesins (proteins) and corresponding receptors [67, 68]. The bacterial adhesion ability depends on hydrophobicity and the intestinal mucus [35]. Generally, 30% of hydrophobicity is considered low/less for adhesion, 30–60% is medium, and more than 60% is high for adhesion [69]. In the present study all the tested 8 isolates (NB7, NB10, NB12, NB14, NB16, NB44, NB94 and NB113) showed a significant (>93.72%)

hydrophobic nature (adherence potential) towards xylene and toluene (>90.86%), NB12 and NB16 showed a significant adherence (more than 62%) to all hydrocarbons and can be considered as potent probiotics as they have the ability to colonize in the digestive tract and establish a barrier and modulate the gut immune system to provide protection towards pathogenic microbes[35,36](Figure3).

**Figure 3: Bacterial Adhesion to Hydrocarbons**




Percentage of adhesion to hydrocarbon, Values are expressed as mean  $\pm$  SD in (n=3).

#### Auto aggregation assay

Auto-aggregation is recommended as a major property to considered lactic acid bacteria as probiotics for adherence to gut epithelial cells by forming bio films to protect the host from colonization of pathogens, it has been reported that above 80% of aggregation is considered to be strong auto-aggregation [70]. In the

present study, 5 out of 8 isolates (NB12, NB14, NB16, NB94 & NB113) exhibited more than 76% and 3 isolates (NB7, NB10 & NB44) exhibited lower than 50% about auto aggregation ability. Overall NB16 and NB12 strains exhibited 90.56% and 88.14% of auto aggregation. Our findings co-relate with the previous results of LAB isolates [2, 45, 40] (Figure-4).

**Figure 4: Auto-aggregation of LAB**



#### Co-aggregation assay


Coaggregation of bacterial strains plays a significant role in control of pathogenic environment and increases the concentration of excreted antimicrobial substances in the human gastrointestinal and urogenital tracts [68, 71]. It has been stated that co-aggregation ability above 50% is considered to be a strong co-aggregation [72]. In the present study, 5 out of 8 isolates (NB12, NB14,

NB16, NB94 and NB113) exhibited more than 55% co-aggregation ability after 5 hours of incubation. NB16 showed a strong co-aggregation with pathogens. Previous studies reported that it depends on strain, species, incubation period, structure composition and forces of the interactions between carbohydrate-lectin and proteinaceous elements existing on the cell surface

[65, 73, 74, 40]. Our studies co-related with previous reports [6, 74, 75] (Figure-5).

### Percentage of Auto-aggregation of LAB

Figure 5: Co-aggregation of the LAB




Co-aggregation of the LAB with food borne pathogens

### Anti-microbial activity

Antimicrobial activity considered as a major property to prevent the growth of the pathogenic microorganism in the digestive tract by producing antimicrobial compounds such as bacteriocins, organic acids, hydrogen peroxide and diacetyl as well as their competition for the nutrients [76, 77]. In the existing study, all 8 isolates (NB7, NB10, NB12, NB14, NB16, NB44, NB94 and NB113) showed resistance against *Salmonella Para typhi* ATCC9150. 4 isolates (NB7, NB10, NB44 and NB94) showed resistance against *Bacillus aureus*, 4 isolates (NB12, NB14, NB16 and NB113) showed resistance against *Salmonella*

*typhimurium* MTCC91. From the selected 8 isolates, all 8 confirmed good *in vitro* inhibitory activity on *Escherichia coli* ATCC10536 & MTCC 40, *Salmonella Arizonae* ATCC 13314 and *Shigella boydii* ATCC 9207 however, inhibitory activity towards pathogens varied within the species (NB12, 14 &113), (NB10, 44 &94), which might be species and strain-dependent [45, 70]. Our findings were correlated with the previous studies [5, 75]. All isolates of lactic acid bacteria were capable of preventing the growth of pathogenic microorganisms and its effect was particularly evident towards pathogens (Figure. 6) (Table 2).

Figure 6: Antibacterial activity of LAB isolates



LAB isolates zone of inhibition against food borne pathogen

**Table 2. Antibacterial activity of selected probiotic LAB against food borne pathogen**


| Probiotic LAB | Pathogenic bacteria (Zone of inhibition) |                                 |                                 |  |                                       |                                       |                                  |
|---------------|--|---------------------------------|---------------------------------|--|---------------------------------------|---------------------------------------|----------------------------------|
|               | <i>Escherichia coli</i> ATCC 10536       | <i>Escherichia coli</i> MTCC 40 | <i>Bacillus cereus</i> MTCC1306 | <i>Salmonella Para typhi murium</i> ATCC9150 | <i>Salmonella typhi murium</i> MTCC91 | <i>Salmonella Arizonae</i> ATCC 13314 | <i>Shigella Boydii</i> ATCC 9207 |
| NB7           | ++                                       | +++                             | -                               | -  | +++                                   | +                                     | +++                              |
| NB10          | +  | +++                             | -                               | -  | ++                                    | ++                                    | +++                              |
| NB 12         | +++                                      | +++                             | ++                              | -  | -                                     | +++                                   | ++                               |
| NB14          | +++                                      | +++                             | +                               | -  | -                                     | ++                                    | +                                |
| NB16          | +++                                      | +++                             | ++                              | -  | -                                     | +++                                   | +++                              |
| NB44          | ++                                       | +++                             | -                               | -  | +++                                   | ++                                    | +++                              |
| NB94          | +++                                      | +++                             | -                               | -  | +++                                   | +                                     | +++                              |
| NB113         | +++                                      | +++                             | +                               | -  | -                                     | +                                     | -                                |

Symbols refer to size of inhibition zone diameter observed with growing cells: -, no inhibition zone; +, 1mm to 3 mm (weak); ++, 3.1 mm to 6.0 mm (good); +++, >6.0 mm (strong).

### Antibiotics susceptibility assay

Antibiotic treatment is the major method followed in the healthcare sector to fight bacterial infections; antibiotic resistance analysis helps to assure the absence of transferable antibiotic resistance genes in any of the probiotic strains and bacterial products which may use as food additives for human consumption, that have to exhibit multidrug-resistant to survive with co-administering of antibiotics [78, 79, 80, 81]. Such resistance characteristic is generally intrinsic and non-

transmissible [82]. In the existing study, 2 out of 8 isolates (NB12, and NB16) were found to be resistant to all the tested antibiotics except *Chloramphenicol*. All 8 isolates were found to be resistant towards *Cefixime*, *Co-Trimoxazole*, *Trimethoprim*, *Nalidixic Acid* and *Ampicillin*. The susceptibility of strains was expressed as described by [49,48]. Our results were correlated with the previous studies [83]. In conclusion, NB12 and NB16 can be recommended as safe for usage for animals and humans (Figure. 7) (Table3).

**Figure 7: Antibiotics susceptibility of LAB isolates**

**antibiotics susceptibility of selected LAB isolates**
**Table 3. Antibiotics resistance of selected probiotic LAB isolates**

| Antibiotics       | Disc Content | Interpretative zone diameter (mm) |       |       |       |       |       |       |       |
|-------------------|--------------|-----------------------------------|-------|-------|-------|-------|-------|-------|-------|
|                   |              | NB16                              | NB7   | NB113 | NB14  | NB10  | NB94  | NB12  | NB44  |
| Ofloxacin         | 5mcg         | 00(R)                             | 00(R) | 00(R) | 20(S) | 15(I) | 12(R) | 10(R) | 10(R) |
| Cefixime          | 5mcg         | 00(R)                             | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) |
| Cefotaxime        | 30mcg        | 00(R)                             | 00(R) | 20(I) | 00(R) | 18(I) | 15(I) | 14(R) | 14(R) |
| Ceftriaxone       | 30mcg        | 00(R)                             | 21(S) | 19(I) | 18(I) | 14(I) | 16(I) | 00(R) | 13(R) |
| Co-Trimoxazole    | 25 mcg       | 00(R)                             | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) |
| Amoxicillin       | 30 mcg       | 15(R)                             | 00(R) | 15(R) | 20(S) | 17(R) | 15(R) | 14(R) | 15(R) |
| Trimethoprim      | 5 mcg        | 00(R)                             | 00(R) | 10(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) |
| Nalidixic Acid    | 30 mcg       | 00(R)                             | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) | 00(R) |
| Ampicillin        | 2mcg         | 00(R)                             | 17(R) | 17(R) | 21(R) | 18(R) | 20(R) | 13(R) | 15(R) |
| Streptomycin      | 10 mcg       | 11(R)                             | 14(I) | 12(I) | 10(R) | 20(S) | 10(R) | 10(R) | 10(R) |
| Oxy tetra cycline | 30mcg        | 14(R)                             | 23(S) | 22(S) | 25(S) | 21(S) | 22(S) | 14(R) | 14(R) |
| Chloramphenicol   | 30mcg        | 17(I)                             | 26(S) | 19(S) | 22(S) | 20(S) | 18(S) | 17(I) | 19(S) |



| Antibiotics   | Disc Content | Interpretative zone diameter (mm) |       |       |       |       |       |       |       |
|---------------|--------------|-----------------------------------|-------|-------|-------|-------|-------|-------|-------|
|               |              | NB16                              | NB7   | NB113 | NB14  | NB10  | NB94  | NB12  | NB44  |
| Ciprofloxacin | 5mcg         | 00(R)                             | 00(R) | 14(R) | 22(S) | 20(I) | 11(R) | 00(R) | 16(R) |
| Azithromycin  | 15 mcg       | 11(R)                             | 23(S) | 19(S) | 28(S) | 16(I) | 22(S) | 00(R) | 13(R) |
| Gentamicin    | 10mcg        | 12(R)                             | 17(S) | 17(S) | 17(S) | 17(S) | 15(S) | 11(R) | 00(R) |

(R)- Resistant; (I) - Intermediate; (S) - Sensitive, in accordance to performance of standards for antimicrobial disk susceptibility test.

## GENOTYPIC CHARACTERIZATION

### DNA isolation and quantification

Genetic characterization of potent probiotic isolates was an important tool to understand the microbial

biodiversity of the genus. The extracted genomic DNA of 8 isolates was analyzed by (1%) agarose gel electrophoresis [84] (Figure 8).

Figure 8: Genomic DNA analysis




Agarose gel (1%) electrophoresis of genomic DNA isolated from the cultures

### Polymerase chain reaction (PCR)

Approximately 10 µl of each resultant PCR product was visualized on agarose gel electrophoresis, a single visible

and sharp band of 8 isolates was observed (98%) (Figure9).

Figure.9: Polymerase chain reaction (PCR)



Agarose gel (1%) electrophoresis of the 16S rDNA PCR amplicons

Demonstrating the highest similarity to *Lactobacillus casei*, *Lactobacillus para casei*, *Enterococcus faecium* and *Enterococcus faecalis* respectively. The 16s rDNA identification showed that NB16 and NB7 strains are 98% identical to *Lactobacillus casei* and *Enterococcus faecalis*, NB12, NB14, NB113 and NB10, NB44, NB94 strains have 98.8% sequence identity to *Lactobacillus para casei* and *Enterococcus faecium*.

## IV. CONCLUSION

In the present study, out of 200 strains, eight strains were identified as *Lactobacillus para casei* (NB12, NB14,

NB113), *Lactobacillus casei* (NB16), *Enterococcus faecium* (NB10, NB44, NB94) and *Enterococcus faecalis* (NB7). Out of eight strains *Lactobacillus para casei* NB16 isolated from breast milk was capable of tolerating high

bile salt, acidic pH and able to survive in synthetic gastric juice and showed the broadest antagonism against a wide extent of food pathogens. In addition, the strain was observed to be resistant to the majority of the antibiotics used, had a strong auto, co-aggregation, hydrophobicity and capable to grow in a range of salt concentration, temperature and pH. Therefore, *Lactobacillus para casei* NB16 has been proved to remain highly effective overall. Our study indicated that breast milk is an excellent resource to isolate lactic acid bacteria with outstanding probiotic characteristics. However, *in vivo* and therapeutic investigations are still required to assure the beneficial roles about the isolates to human health after that can be encouraged for the improvement of new pharmaceuticals and functional food preparations for public health.

#### V. ACKNOWLEDGMENT

The authors acknowledge the support given by DFRL-DRDO, Mysuru - 570011, India, MANF -UGC for their financial support for carrying out the research and Shridevi Institute of Engineering and Technology, Tumakuru - 572106, Karnataka, India.

#### VI. REFERENCES

1. Shehata MG, El Sohaimy SA, El-Sahn MA, Youssef MM. Screening of isolated potential probiotic lactic acid bacteria for cholesterol lowering property and bile salt hydrolase activity. *Annals of Agricultural Sciences*. 2016 Jun 1;61(1):65-75.
2. Angmo K, Kumari A, Bhalla TC. Probiotic characterization of lactic acid bacteria isolated from fermented foods and beverage of Ladakh. *LWT-food Science and Technology*. 2016 Mar 1; 66:428-35.
3. Oh YJ, Jung DS. Evaluation of probiotic properties of *Lactobacillus* and *Pediococcus* strains isolated from Omegisool, a traditionally fermented millet alcoholic beverage in Korea. *LWT-food Science and Technology*. 2015 Sep 1;63(1):437-44.
4. FAO W. Probiotics in food: Health and nutritional properties and guidelines for evaluation. in *FAO Food and Nutritional Paper*. Roma, Italy: FAO/WHO; 2006. p. 85
5. Melia S, Yuherman Y, Jaswandi J, Purwati E. SELECTION OF BUFFALO MILK LACTIC ACID BACTERIA WITH PROBIOTIC POTENTIAL. *Asian Journal of Pharmaceutical and Clinical Research*. 2018: Vol 11.
6. Ayyash M, Abushelaibi A, Al-Mahadin S, Enan M, El-Tarabily K, Shah N. In-vitro investigation into probiotic characterisation of *Streptococcus* and *Enterococcus* isolated from camel milk. *LWT-Food Science and Technology*. 2018 Jan 1; 87:478-87.
7. Salminen S, von Wright A. Current probiotics-safety assured. *Microbial ecology in Health and Disease*. 1998 Jan 1;10(2):68-77.
8. Vidhyasagar V, Jeevaratnam K. Evaluation of *Pediococcus pentosaceus* strains isolated from Idly batter for probiotic properties in vitro. *Journal of Functional Foods*. 2013 Jan 1;5(1):235-43.
9. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. *The American journal of clinical nutrition*. 1999 May 1;69(5):1052s-7s.
10. Rajoka MS, Mehwish HM, Siddiq M, Haobin Z, Zhu J, Yan L, Shao D, Xu X, Shi J. Identification, characterization, and probiotic potential of *Lactobacillus rhamnosus* isolated from human milk. *LWT-Food Science and Technology*. 2017 Oct 1; 84:271-80.
11. Kozak K, Charbonneau D, Sanozky-Dawes R, Klaenhammer T. Characterization of bacterial isolates from the microbiota of mothers' breast milk and their infants. *Gut microbes*. 2015 Nov 2;6(6):341-51.
12. Martín R, Langa S, Reviriego C, Jiménez E, Marín ML, Xaus J, Fernández L, Rodríguez JM. Human milk is a source of lactic acid bacteria for the infant gut. *The Journal of pediatrics*. 2003 Dec 1;143(6):754-8.
13. Rodríguez E, Arqués JL, Rodríguez R, Peirotén Á, Landete JM, Medina M. Antimicrobial properties of probiotic strains isolated from breast-fed infants. *Journal of Functional Foods*. 2012 Apr 1;4(2):542-51.
14. Martín R, Olivares M, Marín ML, Fernández L, Xaus J, Rodríguez JM. Probiotic potential of 3 lactobacilli strains isolated from breast milk. *Journal of Human Lactation*. 2005 Feb;21(1):8-17.
15. Davoodabadi A, Dallal MM, Lashani E, Ebrahimi MT. Antimicrobial activity of *Lactobacillus* spp. isolated from fecal flora of healthy breast-fed infants against diarrheagenic *Escherichia coli*. *Jundishapur journal of microbiology*. 2015 Dec;8(12).
16. Fernandez JM, Quezada SM, Lozano JM, Braquehais FR, Garcia AF, Hernandez AG, Llorente CG, BRITO MB, inventors; Hero AG, assignee. Isolation, identification and characterization of strains with probiotic activity, from faeces of infants fed exclusively with breast milk. United States patent US 8,637,297. 2014 Jan 28.
17. Halimi S, Mirsalehian A. Assessment and comparison of probiotic potential of four *Lactobacillus* species isolated from feces samples of Iranian infants. *Microbiology and immunology*. 2016 Feb;60(2):73-81.
18. Rubio R, Jofré A, Martín B, Aymerich T, Garriga M. Characterization of lactic acid bacteria isolated from infant faeces as potential probiotic starter cultures for fermented sausages. *Food microbiology*. 2014 Apr 1; 38:303-11.

19. Fontana, C., Coconcelli PS, Vignolo G, Saavedra L. Occurrence of antilisterial structural bacteriocins genes in meat borne lactic acid bacteria. *Food Control*. 2015 Jan 1; 47:53-9.
20. Lavilla-Lerma L, Pérez-Pulido R, Martínez-Bueno M, Maqueda M, Valdivia E. Characterization of functional, safety, and gut survival related characteristics of *Lactobacillus* strains isolated from farmhouse goat's milk cheeses. *International journal of food microbiology*. 2013 May 15;163(2-3):136-45.
21. Tejero-Sariñena S, Barlow J, Costabile A, Gibson GR, Rowland I. In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. *Anaerobe*. 2012 Oct 1;18(5):530-8.
22. Handa S, Sharma N. In vitro study of probiotic properties of *Lactobacillus plantarum* F22 isolated from chhang—A traditional fermented beverage of Himachal Pradesh, India. *Journal of Genetic Engineering and Biotechnology*. 2016 Jun 1;14(1):91-7.
23. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. *Journal of applied microbiology*. 2006 Jun;100(6):1171-85.
24. Gao Y, Jia S, Gao Q, Tan Z. A novel bacteriocin with a broad inhibitory spectrum produced by *Lactobacillus sake* C2, isolated from traditional Chinese fermented cabbage. *Food Control*. 2010 Jan 1;21(1):76-81.
25. Mathara JM, Schillinger U, Guigas C, Franz C, Kutima PM, Mbugua SK, Shin HK, Holzapfel WH. Functional characteristics of *Lactobacillus* spp. from traditional Maasai fermented milk products in Kenya. *International Journal of Food Microbiology*. 2008 Aug 15;126(1-2):57-64.
26. Anandharaj M, Sivasankari B, Santhanakaruppu R, Manimaran M, Rani RP, Sivakumar S. Determining the probiotic potential of cholesterol-reducing *Lactobacillus* and *Weissella* strains isolated from gherkins (fermented cucumber) and south Indian fermented koozh. *Research in microbiology*. 2015 Jun 1;166(5):428-39.
27. Chiang SS, Pan TM. Beneficial effects of *Lactobacillus paracasei* subsp. *paracasei* NTU 101 and its fermented products. *Applied Microbiology and Biotechnology*. 2012 Feb 1;93(3):903-16.
28. Shafakatullah N, Chandra M. Screening of Raw Buffalo's Milk from Karnataka for Potential Probiotic Strains. *Research Journal of Recent Sciences*. 2014 Sep 3;9:73-78.
29. Kandler O. Genus *Lactobacillus*. *Bergey's manual of systematic bacteriology*. 1986;2.
30. Sharpe ME, Fryer TF, Smith DG. Identification of the lactic acid bacteria. *Identification methods for microbiologists*. 1979; 2:233-59.
31. Harrigan WF, McCance ME. *Laboratory methods in food and dairy microbiology*. Academic Press Inc. (London) Ltd.; 1976.
32. Tulumoglu S, Yuksekdog ZN, Beyatli Y, Simsek O, Cinar B, Yaşar E. Probiotic properties of lactobacilli species isolated from children's feces. *Anaerobe*. 2013 Dec 1; 24:36-42.
33. Liong MT, Shah NP. Optimization of cholesterol removal by probiotics in the presence of prebiotics by using a response surface method. *Applied and environmental microbiology*. 2005 Apr 1;71(4):1745-53.
34. Fuller, R.. Probiotics in man and animals. *Journal of applied bacteriology*. 1989 May;66(5):365-78.
35. Sánchez-Ortiz AC, Luna-González A, Campa-Córdova ÁI, Escamilla-Montes R, Flores-Miranda MD, Mazón-Suástegu JM. Isolation and characterization of potential probiotic bacteria from pustulose ark (*Anadara tuberculosa*) suitable for shrimp farming. *Latin American Journal of Aquatic Research*. 2015;43(1).
36. Sherman PM, Ossa JC, Johnson-Henry K. Unraveling mechanisms of action of probiotics. *Nutrition in Clinical Practice*. 2009 Feb;24(1):10-4.
37. Rosenberg M. Microbial adhesion to hydrocarbons: twenty-five years of doing MATH. *FEMS microbiology letters*. 2006 Jun 5;262(2):129-34.
38. Kos BV, Šušković J, Vuković S, Šimpraga M, Frece J, Matošić S. Adhesion and aggregation ability of probiotic strain *Lactobacillus acidophilus* M92. *Journal of applied microbiology*. 2003 Jun;94(6):981-7.
39. Gupta A, Sharma N. Characterization of Potential Probiotic Lactic Acid Bacteria-*Pediococcus acidilactici* Ch-2 Isolated from Chuli-A Traditional Apricot Product of Himalayan Region for the Production of Novel Bioactive Compounds with Special Therapeutic Properties. *J Food Microbiol Saf Hyg*. 2017;2(119):2476-059.
40. Del Re B, Sgorbati B, Miglioli M, Palenzona D. Adhesion, autoaggregation and hydrophobicity of 13 strains of *Bifidobacterium longum*. *Letters in applied microbiology*. 2000 Dec;31(6):438-42.
41. Handley PS, Harty DW, Wyatt JE, Brown CR, Doran JP, Gibbs AC. A comparison of the adhesion, coaggregation and cell-surface hydrophobicity properties of fibrillar and fimbriate strains of *Streptococcus salivarius*. *Microbiology*. 1987 Nov 1;133(11):3207-17.
42. Zuo F, Yu R, Feng X, Chen L, Zeng Z, Khaskheli GB, Ma H, Chen S. Characterization and in vitro properties of potential probiotic *Bifidobacterium* strains isolated from breast-fed infant feces. *Annals of microbiology*. 2016 Sep 1;66(3):1027-37.
43. Melia S, Purwati E, Yuherman J, Aritonang SN, Silaen M. Characterization of the Antimicrobial Activity of Lactic Acid Bacteria Isolated from Buffalo Milk in West Sumatera (Indonesia) Against *Listeria monocytogenes*. *Pakistan Journal of Nutrition*. 2017;16(8):645-50.

44. Ennahar S, Sashihara T, Sonomoto K, Ishizaki A. Class IIa bacteriocins: biosynthesis, structure and activity. *FEMS microbiology reviews*. 2000 Jan 1;24(1):85-106.
45. Das P, Khowala S, Biswas S. In vitro probiotic characterization of *Lactobacillus casei* isolated from marine samples. *LWT-Food Science and Technology*. 2016 Nov 1; 73:383-90.
46. Angmo K, Kumari A, Bhalla TC. Probiotic characterization of lactic acid bacteria isolated from fermented foods and beverage of Ladakh. *LWT-food Science and Technology*. 2016 Mar 1; 66:428-35.
47. Jorgensen JH, Turnidge JD. Susceptibility test methods: dilution and disk diffusion methods. In *Manual of Clinical Microbiology*, Eleventh Edition 2015 Jun 1 (pp. 1253-1273). American Society of Microbiology.
48. SCAN, Opinion of the Scientific Committee on Animal Nutrition on the Safety of the Use of *Bacillus* Species in Animal Nutrition. European Commission, Health and Consumer Protection Directorate-General. (SCAN) Scientific Committee on Animal Nutrition. 2000a.
49. National Committee for Clinical Laboratory Standards (2000). Performance standards for antimicrobial disk susceptibility tests. Villanova, PA: NCCLS, Approved Standard: M2-A7. 7th ed.
50. Mora D, Parini C, Fortina MG, Manachini PL. Development of molecular RAPD marker for the identification of *Pediococcus acidilactici* strains. *Systematic and applied microbiology*. 2000 Oct 1;23(3):400-8.
51. Lee KW, Park JY, Jeong HR, Heo HJ, Han NS, Kim JH. Probiotic properties of *Weissella* strains isolated from human faeces. *Anaerobe*. 2012 Feb 1;18(1):96-102.
52. Wang CY, Lin PR, Ng CC, Shyu YT. Probiotic properties of *Lactobacillus* strains isolated from the feces of breast-fed infants and Taiwanese pickled cabbage. *Anaerobe*. 2010 Dec 1;16(6):578-85.
53. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. *Journal of bacteriology*. 1991 Jan 1;173(2):697-703.
54. Çakır İ. Determination of some probiotic properties on *Lactobacilli* and *Bifidobacteria*. Ankara University Thesis of Ph. D. 2003.
55. Doyle MP, Buchanan RL, editors. *Food microbiology: fundamentals and frontiers*. American Society for Microbiology Press; 2012 Dec 28.
56. Charteris WP, Kelly PM, Morelli L, Collins JK. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic *Lactobacillus* and *Bifidobacterium* species in the upper human gastrointestinal tract. *Journal of applied microbiology*. 1998 May;84(5):759-68.
57. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran S, Feeney M, Morrissey D, Thornton G, Fitzgerald G, Daly C, Kiely B. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. In *Lactic Acid Bacteria: Genetics, Metabolism and Applications 1999* (pp. 279-292). Springer, Dordrecht.
58. Vinderola CG, Reinheimer JA (2003). Lactic acid starter and probiotic bacteria, a comparative "in vitro" study of probiotic characteristics and biological barrier resistance. *J. Food Res. Int.* 36: 895-904.
59. Kumar AM, Murugalatha N. Isolation of *Lactobacillus plantarum* from cow milk and screening for the presence of sugar alcohol producing gene. *Journal of Microbiology and Antimicrobials*. 2012 Jan 31;4(1):16-22.
60. Prasad J, Gill H, Smart J, Gopal PK. Selection and characterisation of *Lactobacillus* and *Bifidobacterium* strains for use as probiotics. *International Dairy Journal*. 1998 Dec 1;8(12):993-1002.
61. Mathara JM, Schillinger U, Guigas C, Franz C, Kutima PM, Mbugua SK, Shin HK, Holzapfel WH. Functional characteristics of *Lactobacillus* spp. from traditional Maasai fermented milk products in Kenya. *International Journal of Food Microbiology*. 2008 Aug 15;126(1-2):57-64.
62. Cotter, P.D. Gahan, C.G.M. and Hill, C. 2003. Surviving the Acid Test: Responses of Gram-Positive Bacteria to Low pH. *Microbiol. Mol. Bio. Rev.* 67: 429- 453.
63. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. *FEMS microbiology reviews*. 2005 Sep 1;29(4):625-51.
64. Zárate G, Chaia AP, González S, Oliver G. Viability and  $\beta$ -galactosidase activity of dairy propionibacteria subjected to digestion by artificial gastric and intestinal fluids. *Journal of Food Protection*. 2000 Sep;63(9):1214-21.
65. Collado MC, Meriluoto J, Salminen S. In vitro analysis of probiotic strain combinations to inhibit pathogen adhesion to human intestinal mucus. *Food Research International*. 2007 Jun 1;40(5):629-36.
66. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. *Clinical and diagnostic laboratory immunology*. 2001 Mar 1;8(2):293-6.
67. Zuo F, Yu R, Feng X, Chen L, Zeng Z, Khaskheli GB, Ma H, Chen S. Characterization and in vitro properties of potential probiotic *Bifidobacterium* strains isolated from breast-fed infant feces. *Annals of microbiology*. 2016 Sep 1;66(3):1027-37.
68. Botes, M., Loos, B., van Reenen, C. A., & Dicks, L. M. (2008). Adhesion of the probiotic strain's enterococcus mundtii st4sa and *Lactobacillus plantarum* 423 to caco-2 cells under conditions simulating the intestinal tract, and in the presence of antibiotics and anti-inflammatory medicaments. *Archives of Microbiology*, 190(5), 573-584.

69. Lebeer S, Vanderleyden J, De Keersmaecker SC. Genes and molecules of lactobacilli supporting probiotic action. *Microbiology and Molecular Biology Reviews*. 2008 Dec 1;72(4):728-64.
70. Ilango S, Pandey R, Antony U. Functional characterization and microencapsulation of probiotic bacteria from koozh. *Journal of food science and technology*. 2016 Feb 1;53(2):977-89.
71. Kaewnopparat S, Dangmanee N, Kaewnopparat N, Srichana T, Chulasiri M, Settharaksa S (2013). In vitro probiotic properties of *Lactobacillus fermentum* SK5 isolated from vagina of a healthy woman. *Anaerobe* 22:6-13.
72. Reid G, McGroarty JA, Angotti R, Cook RL. *Lactobacillus* inhibitor production against *Escherichia coli* and coaggregation ability with uropathogens. *Canadian Journal of Microbiology*. 1988 Mar 1;34(3):344-51.
73. Tareb R, Bernardeau M, Gueguen M, Vernoux JP. In vitro characterization of aggregation and adhesion properties of viable and heat-killed forms of two probiotic *Lactobacillus* strains and interaction with foodborne zoonotic bacteria, especially *Campylobacter jejuni*. *Journal of Medical Microbiology*. 2013 Apr 1;62(4):637-49.
74. Taheur FB, Kouidhi B, Fdhila K, Elabed H, Slama RB, Mahdouani K, Bakhrouf A, Chaieb K. Anti-bacterial and anti-biofilm activity of probiotic bacteria against oral pathogens. *Microbial pathogenesis*. 2016 Aug 1; 97:213-20.
75. Šušković J, Brkić B, Matošić S, Marić V. *Lactobacillus acidophilus* M92 as potential probiotic strain. *Milchwissenschaft*. 1997 Jan 1;52(8):430-5.
76. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut-. *The American journal of clinical nutrition*. 2001 Feb 1;73(2):399s-405s.
77. Tambekar, D.H., Bhutada, S.A., Choudhary, S.D., Khond, M.D., 2009. Assessment of potential probiotic bacteria isolated from milk of domestic animals. *J. Appl. Biosci.* 15, 815–819.
78. Vankerckhoven V, Huys G, Vancanneyt M, Vael C, Klare I, Romond MB, Entenza JM, Moreillon P, Wind RD, Knol J, Wiertz E. Biosafety assessment of probiotics used for human consumption: recommendations from the EU-PROSAFE project. *Trends in Food Science & Technology*. 2008 Feb 1;19(2):102-14.
79. Zhou KZ, Yim CK, Tse DK. The effects of strategic orientations on technology-and market-based breakthrough innovations. *Journal of marketing*. 2005 Apr 1;69(2):42-60.
80. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP). Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. *EFSA Journal*. 2012 Jun;10(6):2740.
81. Courvalin P. Vancomycin resistance in gram-positive cocci. *Clinical Infectious Diseases*. 2006 Jan 1;42(Supplement\_1):S25-34.
82. Erdogru O, Erbilir F (2006). Isolation and Characterization of *Lactobacillus bulgaricus* and *Lactobacillus casei* from various foods. *Turk. J. Biol.*, 30: 39-44.
83. Verdenelli MC, Ghelfi F, Silvi S, Orpianesi C, Cecchini C, Cresci A. Probiotic properties of *Lactobacillus rhamnosus* and *Lactobacillus paracasei* isolated from human faeces. *European journal of nutrition*. 2009 Sep 1;48(6):355-63.
84. Heilig, H.G., Zoetendal, E.G., Vaughan, E.E., Marteau, P., Akkermans, A.D. and de Vos, W.M., 2002. Molecular diversity of *Lactobacillus* spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. *Applied and environmental microbiology*, 68(1), pp.114-123.

Received:01.08.18, Accepted: 06.09.18, Published:01.10.2018

**\*Corresponding Author:**

**Farhath Khanum\***

Email: [farhathkhanum@gmail.com](mailto:farhathkhanum@gmail.com)